> Chemicals & Drugs > Organic Chemical > RAD 001

RAD 001

Q: What are the different variations or types of RAD 001?

RAD 001 is the generic name for the pharmaceutical agent everolimus, which is a specific type of mTOR inhibitor. It is primarily used in cancer treatment and immunosuppression. There are no major variations or types of RAD 001 itself, but it may be formulated and administered in different ways depending on the specific medical application.

Q: How can RAD 001 be used in cancer treatment?

RAD 001 has been approved for the treatment of several types of cancer, including advanced renal cell carcinoma, hormone receptor-positive breast cancer, and progressive neuroendocrine tumors of pancreatic origin. It works by inhibiting the mTOR pathway, which is involved in cell growth and proliferation, effectively slowing the progression of certain cancers.

RAD 001 is a pharmaceutical agent used in cancer treatment and immunosuppression.
It is an mTOR inhibitor that blocks cell growth and proliferation.
PubCompare.ai's AI-driven platform can help optimize your RAD 001 research by easily identifying the most effective protocols from literature, preprints, and patents.
Their advanced analysis compares protocols to help you make more informed decisions and streamline your workflow.
With PubCompare.ai, you can find the best approaches for your RAD 001studies.

Most cited protocols related to «RAD 001»

Volumetric MRI Analysis of Tumor Burden

Cited 9 times

To determine the reproducibility of the volumetric MRI analysis in tumor bearing mice, one observer (ED) applied the method to the tumors of 10 randomly selected mice on three different days. We obtained mouse MRIs at age of 4, 6, 8 10 and 12 months for a natural history study; at age of 6, 7 and 9 months for the RAD001 treatment groups; and at age 5, 7, 9 and 11 months for the Sorafenib treatment groups. On the above described 3D RARE sequence, the plexiform neurofibromas appear bright in contrast to most other tissues. Medx software (Medical Numerics, Inc., Germantown, MD) was used for volumetric analysis. One observer (ED) manually outlined lesions on each MRI slice containing tumor. Tumor on the left and right side of each mouse was measured separately at the cervical and thoracic levels, where the bulk of tumor was identified. Smaller cauda equine tumors were not included in the analysis, as the resolution in this region limited accuracy. Measurement error increases for tumors with volumes <10mm³, therefore, we report only tumors with volumes >10mm³. The tumor criteria were based on image resolution and MRI section slice thickness similar to those described previously [3 (link)]. The program calculated tumor volume from the area of graphic outline and MRI slice thickness. All volumes are reported as combined tumor volume in an individual mouse.

Wu J., Dombi E., Jousma E., Dunn R.S., Lindquist D., Schnell B.M., Kim M.O., Kim A., Widemann B.C., Cripe T.P, & Ratner N. (2011). Preclincial Testing of Sorafenib and RAD001 in the Nf fl/fl;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging. Pediatric blood & cancer, 58(2), 173-180.

Publication 2011

Dietary Fiber Equus caballus Mus Neck Neoplasms Plexiform Neurofibroma RAD 001 Sorafenib Tail Tissues

Lung Cancer Xenograft Establishment and Treatment

Cited 4 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2015

Animals BDA-366 Cells Heterografts Inhalation Institutional Animal Care and Use Committees Lung Cancer Males Mice, Nude Mus Neoplasms pathogenesis RAD 001 Subcutaneous Tissue Tissues

Immunohistochemistry and Immunofluorescence Analysis

Cited 3 times

IHC analysis staining was performed as previously described 23 (link). Antibodies against ITGA5 (diluted 1:50), EFNB2 (diluted 1:200), p-S6 (diluted 1:75), Ki-67 (diluted 1:100) and CD31 (diluted 1:100) were used. A modified histologic score (H-scores, [{% of weak staining} × 1] + [{% of moderate staining} × 2] + [{% of strong staining} × 3]) was used to evaluate IHC staining 24 (link), 25 (link). Each staining obtained an H-score between 0 and 300, and the average of H-score for all the cases was calculated.
For IF assays, Cells were treated with DMSO, Rapa (20 nM), RAD001 (50 nM) or MHY1485 (10 µM) for 24 h and then stained as previously described 23 (link). Primary antibodies against ITGA5 (diluted 1:50), EFNB2 (diluted 1:200), or CD44 (diluted 1:1000) and FITC-conjugated secondary antibody (diluted 1:1000) were used. DAPI (Beyotime) was used to stain nuclei. The images were captured by LSM880 + Airyscan confocal laser scanning microscope (Carl Zeiss, Oberkochen, Germany).

Li D., Sun A., Zhang L., Ding Z., Yi F., Yang X., Wang Z., Chen X., Liu W., Liu S., Shen H., Miao M., Zhang L., Liu P., Liu Y., Su S., Huang H., Huang C., Hu Z., Zhang H., Zha X, & Liu Y. (2022). Elevated ITGA5 facilitates hyperactivated mTORC1-mediated progression of laryngeal squamous cell carcinoma via upregulation of EFNB2. Theranostics, 12(17), 7431-7449.

Full text: Click here

Publication 2022

Antibodies Biological Assay CD44 protein, human Cell Nucleus Cells DAPI Debility Fluorescein-5-isothiocyanate Immunoglobulins ITGA5 protein, human MHY1485 Microscopy, Confocal RAD 001 Stains Sulfoxide, Dimethyl

Biodistribution and Imaging of Radiolabeled Minigastrin

Cited 3 times

All experiments were performed in accordance with Swiss Animal Protection Laws. For tumor implantation, 5 × 10⁶ of A431/CCKBR cells in 0.1 mL of phosphate-buffered saline (PBS) containing 0.9% NaCl were injected subcutaneously (two tumors per animal) into CD-1 female nude mice (Charles Rivers, Germany) anesthetized by isoflurane/oxygen inhalation. After 5 days, the animals were randomly distributed into experimental groups and the tumor size was measured non-invasively with a caliper and the average tumor volumes were estimated for each group. RAD001 (3 mg/kg), metformin (200 mg/kg) or PBS (control) were administered daily via intraperitoneal injection. RAD001 and metformin doses were selected based on the previous animal studies, which show anti-tumor activity and no toxicity in the nude mice 26 (link), 27 (link). In the biodistribution study, mice received 3 pmol of radiolabeled [¹⁷⁷Lu]Lu-PP-F11N into the tail vein (150 kBq in 0.1 mL PBS), for blocking 60 nmol minigastrin was co-injected and 4 h later the mice were subjected to euthanasia with CO₂. Dissected tumors and organs were weighed and measured using the gamma counter.
For SPECT/CT imaging, [¹⁷⁷Lu]Lu-PP-F11N was purified by HPLC and 0.2 nmol of radiolabeled [¹⁷⁷Lu]Lu-PP-F11N was diluted in PBS (10 MBq in 100 µl). Two hours after i.v. injection, mice were sacrificed and subjected to 10 min X-ray computed tomography (CT) followed by 5 h single-photon emission computed tomography (SPECT) using a multipinhole small-animal NanoSPECT/CT camera (Mediso Medical Imaging Systems). Image reconstruction and quantification was accomplished by using connecting thresholding and Otsu method (VivoQuant 3.0 Patch1).

Grzmil M., Qin Y., Schleuniger C., Frank S., Imobersteg S., Blanc A., Spillmann M., Berger P., Schibli R, & Behe M. (2020). Pharmacological inhibition of mTORC1 increases CCKBR-specific tumor uptake of radiolabeled minigastrin analogue [177Lu]Lu-PP-F11N. Theranostics, 10(24), 10861-10873.

Full text: Click here

Publication 2020

Animals Cells Euthanasia Gamma Rays High-Performance Liquid Chromatographies Inhalation Injections, Intraperitoneal Isoflurane Lutetium-177 Metformin Mice, Nude minigastrin Mus Neoplasms Normal Saline Ovum Implantation Oxygen Phosphates RAD 001 Rivers Saline Solution Single Photon Emission Computed Tomography Computed Tomography Tail Tomography, Emission-Computed, Single-Photon Tomography, X-Ray Veins Woman X-Ray Computed Tomography

In Vivo Evaluation of Targeted Therapies for Neurofibromas

Cited 3 times

RAD001: We used RAD001 instead of its analog rapamycin because of improved oral availability [17 (link)]. The RAD001 dose was chosen based on studies in which daily oral administration of RAD001 at 10 mg/kg produced transient tumor stasis in an MPNST xenograft model [12 (link)] and after a preliminary tolerated dose study in the neurofibroma mouse model (not shown). Seven-month old Nf1^flox/flox;DhhCre mice (n=15) were imaged by MRI followed by daily oral gavage for 8 weeks of RAD001 (10 mg/kg) diluted in 3 vehicle carrier. Vehicle-treated mice (n=5) were gavaged daily with the same solution lacking RAD001. These animals were re-imaged by MRI at 9 months of age after the completion of the last dose.
For the Sorafenib trial, 9-month old Nf1^flox/flox;DhhCre mice (n=10) were imaged by MRI then treated with Sorafenib (45mg/kg) daily by oral gavage. This Sorafenib dose was chosen based on preclinical studies in which daily oral administration of Sorafenib at 30 to 60 mg/kg produced complete tumor stasis during treatment in five of six tumor models tested [15 (link),18 (link)] and a preliminary maximum tolerated dose test in this neurofibroma mouse model (not shown). A control group (n=4) received 200 μl of vehicle daily.

Publication 2011

Administration, Oral Animals CCI 779 Heterografts Malignant Peripheral Nerve Sheath Tumor Mus Neoplasms Neurofibroma RAD 001 Sorafenib Transients Tube Feeding

Most recents protocols related to «RAD 001»

Antifungal Agents Evaluation Protocol

EVL (RAD001, 99.69%) was obtained from Selleck Chemicals LLC (TX, USA). ITC and AMB were from Macklin (Shanghai, China). VRC and POS were from Solarbio Biotechnology (Beijing, China). RPMI-1640 was from Gen-view Scientific Inc. (FL, USA). All reagents were prepared as per Clinical and Laboratory Standards Institute M38-A2 guidelines (CLSI, 2008).

An L., Jia G., Tan J., Yang L., Wang Y, & Li L. (2023). Analysis of the synergistic antifungal activity of everolimus and antifungal drugs against dematiaceous fungi. Frontiers in Cellular and Infection Microbiology, 13, 1131416.

Full text: Click here

Publication 2023

Clinical Laboratory Services RAD 001

Serum Starvation and Pharmacological Inhibition

Fibroblast cultures were grown to ∼70 to 80% confluence in 10-cm dishes or 6-well plates and were serum starved for 12 h. During pharmacological inhibition experiments, inhibitors were added at the 11th h of starvation. After starvation, cells were refed with fresh media. Inhibitors were present during refeeding in the respective experiments. Inhibitors were used at the following concentrations: BKM120 (2 μM), AZD5363 (1 μM), RAD001 (40 nM), FR180204 (100 μM), U0126 (25 μM), PD980595 (50 μM), Torin-1 (40 nM), sapanisertib (125 nM), and Rapalink-1 (10 nM). Media were removed, and cells were washed in PBS and scraped on ice with ice-cold lysis buffer [1% digitonin, 150 mM NaCl, 50 mM Tris (pH 7.4), 10 mM NaF, 2 mM sodium orthovanadate, protease inhibitor cocktail (Sigma-Aldrich), and phosphatase inhibitor cocktail (Sigma-Aldrich)] and transferred to a centrifuge tube. After 15 min of incubation on ice, samples were centrifuged at high speed for 15 min to remove nuclei and debris. The protein concentration of the lysate was determined with a Pierce BCA assay (Thermo Fisher).

Wehle D.T., Bass C.S., Sulc J., Mirzaa G, & Smith S.E. (2023). Protein interaction network analysis of mTOR signaling reveals modular organization. The Journal of Biological Chemistry, 299(11), 105271.

Full text: Click here

Publication 2023

AZD5363 Biological Assay Buffers Cell Nucleus Cells Cold Temperature Digitonin Fibroblasts FR 180204 Hyperostosis, Diffuse Idiopathic Skeletal inhibitors NVP-BKM120 Orthovanadate Phosphoric Monoester Hydrolases Protease Inhibitors Proteins Psychological Inhibition RAD 001 RapaLink-1 sapanisertib Serum Sodium Sodium Chloride torin Tromethamine U 0126

Western Blotting Antibody Panel

The following antibodies for the purpose of Western blotting were acquired from Cell Signaling Technologies: pAKT S473 (Catalog number 4060), PAN-AKT (#2920), Phospho-p44/42 MAPK (#4370), p44/42 MAPK (#4695), S6 Ribosomal Protein (#2317), Phospho-S6 Ribosomal Protein (#4858), Phospho-p70S6 Kinase Thr389 (#97596), p70S6 Kinase (#9202), Phospho-4EBP1 Thr37/46 (#2855), 4EBP1 (#9452). Antibodies against Beta-Actin were purchased from GeneTex (catalog number 109639). MAPK inhibitors were purchased from Tocris: FR180204 (catalog number 3706), U0126 (catalog number 1144), PD980595 (catalog number 1213). Sapanisertib (Cat# HY-13328) and Rapalink-1 (Cat# HY-111373) were purchased from MedChemExpress. Torin-1 (Cat #4247) was purchased from Tocris. PI3K/AKT/mTOR inhibitors BKM120 (Buparlisib; Novartis), AZD5363 (Capivasertib; Selleckchem), and RAD001 (Everolimus, MedChemExpress Cat# 159351–69–6) were generously provided by Dr Kathleen Millen.

Full text: Click here

Publication 2023

Antibodies AZD5363 beta-Actin buparlisib capivasertib EIF4EBP1 protein, human Everolimus FR 180204 FRAP1 protein, human inhibitors Mitogen-Activated Protein Kinase 3 NVP-BKM120 RAD 001 RapaLink-1 Ribosomal Proteins Ribosomal Protein S6 Kinases, 70-kDa sapanisertib torin U 0126

Engineered Breast Cancer Cell Lines for Everolimus Resistance

CAMA-1 (ATCC HTB-21) and MCF7 (ATCC HTB-22) human BC cell lines were maintained in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS, Sigma-Aldrich #12306C) and antibiotic–antimycotic solution. T47D (ATCC HTB-133) human BC cell line was maintained in RPMI supplemented with 10% FBS and antibiotic–antimycotic solution. Cells were regularly tested for mycoplasma contamination using commercially available Mycoplasma detection kit (Myco Alert kit, Lonza). Cell lines were authenticated using STR profiling (Laragen, Inc). Everolimus (RAD001, #S1120) and ONC201/TIC10 (#S7963) were obtained from Selleckchem and dissolved in DMSO.
Everolimus resistant cell lines were generated by long-term culture of parental cell lines in the continuous presence of 100 nM everolimus (MCF7 and T47D) or 50 nM everolimus (CAMA-1) with fresh media and drug replenished every 3 days, until resistance developed (6–12 months). Resistance to everolimus was confirmed by the difference in the drug dose–response in comparison with the parental cells, measured using CellTiter-Glo Luminescent Cell Viability Assay (Promega Corporation #G7573). Everolimus resistant cells were further maintained in complete culture medium supplemented with 50 nM everolimus (CAMA-1) or 100 nM everolimus (MCF7 and T47D). Sensitive and resistant cells were labeled with Venus (LeGO-V2 Addgene #27340) and mCherry (LeGO-C2 Addgene #27339) fluorescent proteins, respectively, as described previously (Grolmusz et al., 2020 (link); Weber et al., 2008 (link)).

Farmaki E., Nath A., Emond R., Karimi K.L., Grolmusz V.K., Cosgrove P.A, & Bild A.H. (2023). ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer. eLife, 12, e85898.

Full text: Click here

Publication 2023

Antibiotics Camassia Cell Lines Cells Cell Survival Culture Media Eagle Everolimus Homo sapiens Luminescent Measurements MCF-7 Cells Mycoplasma ONC201 Parent Pharmaceutical Preparations Promega Proteins RAD 001 Sulfoxide, Dimethyl TIC10 compound

Inhibitory Effects on TGEV Replication

JR-AB2-011 (MCE HY-122022), everolimus (MCE RAD001), and rapamycin (MCE HY-10219) were dissolved in dimethyl sulfoxide at a stock concentration of 10 mM and then frozen in aliquots at −80°C. The cells were incubated with the specified concentration of inhibitor for 2 hours and then infected with TGEV at an MOI of 0.01. Then, the cells were prepared for immunofluorescence assays at 24 hpi, and the supernatants were collected for viral titer assays.

Fu Y., Fu Z., Su Z., Li L., Yang Y., Tan Y., Xiang Y., Shi Y., Xie S., Sun L, & Peng G. (2023). mLST8 is essential for coronavirus replication and regulates its replication through the mTORC1 pathway. mBio, 14(4), e00899-23.

Full text: Click here

Publication 2023

Biological Assay Cells Everolimus Freezing Immunofluorescence RAD 001 Sirolimus Sulfoxide, Dimethyl

Top products related to «RAD 001»

Rad001 by Selleck Chemicals

Sourced in United States, China

RAD001 is a laboratory equipment used for analyzing and measuring various chemical and biological samples. It is designed to provide accurate and precise measurements of specific parameters within the samples. The core function of RAD001 is to perform analytical tasks, but a more detailed description cannot be provided while maintaining an unbiased and factual approach.

Rad001 by Novartis

Sourced in Switzerland, United States

RAD001 is a laboratory instrument designed for research and analysis. It provides a platform for various scientific applications. The core function of RAD001 is to facilitate data collection and processing in a controlled environment.

Mk 2206 by Selleck Chemicals

Sourced in United States, China, United Kingdom, Germany

MK-2206 is a selective allosteric Akt inhibitor that binds to the pleckstrin homology (PH) domain of Akt and inhibits its phosphorylation and activation. It has been used in research applications to study the role of Akt signaling in various cellular processes.

Everolimus rad001 by Selleck Chemicals

Sourced in United States, Australia

Everolimus (RAD001) is a mTOR inhibitor, a class of immunosuppressant drugs. It functions by blocking the mammalian target of rapamycin (mTOR), a protein kinase that regulates cell growth, proliferation, and survival. Everolimus is used in research applications to study cellular pathways and signaling mechanisms.

Fetal bovine serum (fbs) by Thermo Fisher Scientific

Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal

Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.

Dimethyl sulfoxide (dmso) by Merck Group

Sourced in United States, Germany, United Kingdom, China, Italy, Sao Tome and Principe, France, Macao, India, Canada, Switzerland, Japan, Australia, Spain, Poland, Belgium, Brazil, Czechia, Portugal, Austria, Denmark, Israel, Sweden, Ireland, Hungary, Mexico, Netherlands, Singapore, Indonesia, Slovakia, Cameroon, Norway, Thailand, Chile, Finland, Malaysia, Latvia, New Zealand, Hong Kong, Pakistan, Uruguay, Bangladesh

DMSO is a versatile organic solvent commonly used in laboratory settings. It has a high boiling point, low viscosity, and the ability to dissolve a wide range of polar and non-polar compounds. DMSO's core function is as a solvent, allowing for the effective dissolution and handling of various chemical substances during research and experimentation.

Rad001 by LC Laboratories

Sourced in United States

RAD001 is a laboratory equipment product manufactured by LC Laboratories. It is a versatile instrument designed for scientific research and experimentation. The core function of RAD001 is to perform precise measurements and analyses of various samples and materials.

Matrigel by BD

Sourced in United States, United Kingdom, Germany, China, Canada, Japan, Italy, France, Belgium, Australia, Uruguay, Switzerland, Israel, India, Spain, Denmark, Morocco, Austria, Brazil, Ireland, Netherlands, Montenegro, Poland

Matrigel is a solubilized basement membrane preparation extracted from the Engelbreth-Holm-Swarm (EHS) mouse sarcoma, a tumor rich in extracellular matrix proteins. It is widely used as a substrate for the in vitro cultivation of cells, particularly those that require a more physiologically relevant microenvironment for growth and differentiation.

Bkm120 by Novartis

Sourced in Switzerland, United States

BKM120 is a laboratory research tool produced by Novartis. It is a small molecule inhibitor that targets the phosphoinositide 3-kinase (PI3K) signaling pathway. The core function of BKM120 is to serve as a research instrument for studying cellular processes and signaling mechanisms involving the PI3K pathway.

Rapamycin by LC Laboratories

Sourced in United States, Germany, United Kingdom, Canada, Morocco, Macao

Rapamycin is a macrolide compound produced by the bacterium Streptomyces hygroscopicus. It functions as an immunosuppressant and has been used in research applications.

What are the different variations or types of RAD 001?

How can RAD 001 be used in cancer treatment?

What are some common usage challenges with RAD 001?

One of the main challenges with RAD 001 is managing the side effects, which can include fatigue, diarrhea, and mouth sores. Careful monitoring and dose adjustments may be required to find the optimal balance between efficacy and tolerability for each patient. Additionally, RAD 001 can interact with certain other medications, so healthcare providers must be vigilant about potential drug interactions.

How can PubCompare.ai assist with RAD 001 research?

PubCompare.ai's AI-driven platform can help optimize your RAD 001 research in several ways. First, it allows you to screen protocol literature more efficiently by leveraging AI to pinpoit critical insights. Second, the platform's advanced analysis can highlight key differences in protocol effectiveness, enabling you to choose the best approach for your specific research goals and ensure reproducibility and accuracy. This can be especially helpful when trying to identify the most effective protocols related to RAD 001 from the available literature, preprints, and patents.

How does PubCompare.ai's AI analysis help with RAD 001 research?

PubCompare.ai's AI-driven analysis can help researchers make more informed decisions and streamline their RAD 001 workflow. The platform's advanced algorithms are able to compare protocols in depth, identifying critical insights that may not be immediately obvious. This enables researchers to pinpoint the most effective protocols for their specific needs, whether that's maximizing efficacy, minimizing side effects, or improving reproducibility. By leveraging PubCompare.ai, researchers can save time and confidently choose the best approaches for their RAD 001 studies.

More about "RAD 001"

Rad 001, also known as Everolimus, is a potent mTOR inhibitor that has been extensively studied for its anti-cancer and immunosuppressive properties.
This pharmaceutical agent is commonly used in the treatment of various types of cancers, including renal cell carcinoma, breast cancer, and neuroendocrine tumors.
Rad 001 works by blocking the mammalian target of rapamycin (mTOR) pathway, which is a crucial regulator of cell growth, proliferation, and survival.
Rad 001 has been shown to be effective in inhibiting the growth and proliferation of cancer cells, making it a valuable tool in cancer research and treatment.
In addition to its anti-cancer effects, Rad 001 has also been used in the field of immunosuppression, particularly in the context of organ transplantation, where it helps to prevent rejection of the transplanted organ.
To further optimize Rad 001 research, researchers can utilize the AI-driven platform offered by PubCompare.ai.
This platform enables researchers to easily identify the most effective protocols from the literature, preprints, and patents, by comparing and analyzing the available data.
The advanced AI-powered analysis provided by PubCompare.ai can help researchers make more informed decisions and streamline their workflow, ultimately leading to more efficient and productive Rad 001 studies.
When working with Rad 001, researchers may also encounter other related compounds and reagents, such as MK-2206, an Akt inhibitor, and Everolimus, which is a derivative of Rad 001.
Additionally, cell culture techniques involving the use of fetal bovine serum (FBS), dimethyl sulfoxide (DMSO), and Matrigel may be employed.
Researchers may also explore the use of BKM120, a PI3K inhibitor, and Rapamycin, another mTOR inhibitor, in combination with Rad 001 to enhance its efficacy.
By leveraging the insights and tools provided by PubCompare.ai, researchers can optimize their Rad 001 studies and uncover the most effective protocols, leading to advancements in cancer treatment and immunosuppression research.